arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
Published 1 year ago • 444 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:14
arasens: dialuramide plus adt and docetaxel in mhspc stratified by disease risk volume
-
0:51
os sensitivity analysis of darolutamide, docetaxel and adt in arasens
-
1:44
arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
1:19
role of the addition of docetaxel to adt in mhspc
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
1:53
arasens: tolerability pharmacokinetic analyses of combo therapy with daro, adt and doc in mhspc
-
5:49
adt plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: systemic review
-
3:27
chaarted: adt docetaxel for prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:41
the role of triplet therapy in men with metastatic castration sensitive prostate cancer
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer
-
0:47
systemic triple therapy in metastatic hormone-sensitive prostate cancer
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
1:42
darolutamide and survival in mhspc: a plain language summary of the arasens study
-
55:35
is there still a role for docetaxel in mhspc?
-
2:07
dr. kantoff on docetaxel plus androgen deprivation therapy in prostate cancer